Plasma Cell Myeloma
| Primary Site | Histology | Behavior |
|---|---|---|
| C000-C699, C739-C750, C754-C809 | 9732 | <Any value> |
| C700-C729, C751-C753 | 9732 | 3 |
Notes
9732 Multiple myeloma **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** TNM data elements are not defined for this schema. TNM Stage Group is defined for multiple myeloma only (see Note 3) **Note 3:** The *Revised International Staging System (RISS)* is being used to stage plasma cell myeloma/multiple myeloma (9732). The following variables must be collected at the time of diagnosis for staging: * High Risk Cytogenetics [NAACCR Data Item #3857] * LDH Pretreatment Level [NAACCR Data Item #3932] * Serum Albumin Pretreatment Level [NAACCR Data Item #3930] * Serum Beta-2 Microglobulin Pretreatment Level [NAACCR Data Item #3931]Data Items
| Name | Default Value | Used for Staging | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | <BLANK> | No |
NAACCR #390
dateOfDiagnosis |
None | |
| Primary Site | <BLANK> | Yes |
NAACCR #400
primarySite |
None | |
| Histology | <BLANK> | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | |
| Behavior | <BLANK> | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | |
| Schema Discriminator 1 | 0 | Yes |
NAACCR #3926
schemaDiscriminator1 |
All | SSDI |
| Tumor Size Clinical | 999 | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | 999 | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| LVI | 8 | No |
NAACCR #1182
lymphVascularInvasion |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 88 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | <BLANK> | No |
NAACCR #764
summaryStage2018 |
None | |
| Grade Clinical | 8 | No |
NAACCR #3843
gradeClinical |
CCCR/Canada COC NPCR SEER |
SSDI |
| Grade Pathological | 8 | No |
NAACCR #3844
gradePathological |
CCCR/Canada COC NPCR SEER |
SSDI |
| Grade Post Therapy Clin (yc) | <BLANK> | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI |
| Grade Post Therapy Path (yp) | <BLANK> | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI |
| Serum Beta-2 Microglobulin Pretreatment Level | 9 | No |
NAACCR #3931
serumBeta2MicroglobulinPretxLvl |
CCCR/Canada COC SEER |
SSDI |
| Serum Albumin Pretreatment Level | 9 | No |
NAACCR #3930
serumAlbuminPretreatmentLevel |
CCCR/Canada COC SEER |
SSDI |
| High Risk Cytogenetics | 9 | No |
NAACCR #3857
highRiskCytogenetics |
CCCR/Canada COC SEER |
SSDI |
| LDH Level | 9 | No |
NAACCR #3869
ldhPretreatmentLevel |
CCCR/Canada COC SEER |
SSDI |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 00821 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None |